Wu Xuemin, Chen Rujing, Chen Qiuyong, Che Yongliang, Yan Shan, Zhou Lunjiang, Wang Longbai
Fujian Academy of Agriculture Sciences/Fujian Animal Disease Control Technology Development Center, Institute of Animal Husbandry and Veterinary Medicine, Fuzhou, China.
J Med Virol. 2023 Jan;95(1):e28228. doi: 10.1002/jmv.28228.
Pseudorabies virus (PRV), as a neuroherpes virus, leads to heavy economic losses in the pig industry worldwide. This study was designed to establish recombinant PRV glycoprotein B (gB), C, and D proteins as PRV diagnostic antigens. The gB/C, gC/D, and gB/C/D fusion sequences were synthesized and inserted into pET-28a vector to generate the recombinant plasmids. The identified positive recombinant plasmids were transformed into BL21 Escherichia coli. The results of the polymerase chain reaction and enzyme digestion showed that the gB/C, gC/D, and gB/C/D fusion proteins were successfully expressed. An indirect sandwich ELISA was developed with the gB/C, gC/D, and gB/C/D as coating antigens. The results of indirect enzyme-linked immunosorbent assay (ELISA) analysis of 184 PRV-positive porcine sera showed that the positive coincidence rates of three recombinant proteins ELISAs relative to IDEXX kit were 98.25%, 95.32%, and 98.83%, and the negative coincidence rates were 85.71%, 75% and 100%, respectively. The inter and intra batch repeatability tests showed that the coefficient of variations of our kits were all less than 5%. Especially, the gB/C/D-ELISA has the highest specificity and sensitivity among the ELISA methods developed in this study. We established a series expression system of gB/C, gC/D, and gB/C/D antigen epitope genes and Recombinant protein-based indirect ELISA, providing new ideas for PV diagnosis and vaccine development.
伪狂犬病病毒(PRV)作为一种神经疱疹病毒,给全球养猪业造成了巨大的经济损失。本研究旨在构建重组PRV糖蛋白B(gB)、C和D蛋白作为PRV诊断抗原。合成gB/C、gC/D和gB/C/D融合序列并插入pET-28a载体以产生重组质粒。将鉴定出的阳性重组质粒转化到BL21大肠杆菌中。聚合酶链反应和酶切结果表明,gB/C、gC/D和gB/C/D融合蛋白成功表达。以gB/C、gC/D和gB/C/D作为包被抗原建立了间接夹心ELISA。对184份PRV阳性猪血清进行间接酶联免疫吸附测定(ELISA)分析的结果表明,三种重组蛋白ELISA相对于IDEXX试剂盒 的阳性符合率分别为98.25%、95.32%和98.83%,阴性符合率分别为85.71%、75%和100%。批内和批间重复性试验表明,我们试剂盒的变异系数均小于5%。特别是,gB/C/D-ELISA在本研究开发的ELISA方法中具有最高的特异性和敏感性。我们建立了gB/C、gC/D和gB/C/D抗原表位基因的系列表达系统以及基于重组蛋白的间接ELISA,为PRV诊断和疫苗开发提供了新思路。